Fig. 2From: Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record reviewIncidence of reported multiple sclerosis symptoms at the baseline visit. *P ≤ 0.05 for 3-way comparison. DMF = dimethyl fumarate; FTY = fingolimod; TFN = teriflunomideBack to article page